Basal cell carcinoma (BCC), the most common type of skin cancer, is characterized by aberrant activation of the hedgehog molecular pathway. Systemic therapy is indicated when local approaches, such as surgery and radiation, are inappropriate. In this article, a group of clinical experts recommends the long-term management strategy for advanced BCC patients treated with systemic therapy. The hedgehog inhibitors sonidegib and vismodegib are first-line treatments for advanced BCC with a long-lasting response, but long-term treatment with hedgehog inhibitors is often challenged by tolerability issues. However, several strategies for adverse effect management are available, such as dose interruptions, on-label alternate-day dosing and supportive medications. In conclusion, although BCC shows a high tumor mutational burden that favors a response to immunotherapy, experts recommend keeping patients on hedgehog inhibitors limiting immunotherapy to those who developed resistance during hedgehog inhibitor therapy or in case of persisting toxicity despite long-term management of adverse events.

Bossi, P., Ascierto, P. A., Basset-Seguin, N., Dreno, B., Dummer, R., Hauschild, A., Mohr, P., Kaufmann, R., Pellacani, G., Puig, S., Moreno-Ramirez, D., Robert, C., Stratigos, A., Gutzmer, R., Queirolo, P., Quaglino, P., Peris, K., Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors, <<CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY>>, 2023; 189 (september): 104066-N/A. [doi:10.1016/j.critrevonc.2023.104066] [https://hdl.handle.net/10807/249070]

Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors

Peris, Ketty
2023

Abstract

Basal cell carcinoma (BCC), the most common type of skin cancer, is characterized by aberrant activation of the hedgehog molecular pathway. Systemic therapy is indicated when local approaches, such as surgery and radiation, are inappropriate. In this article, a group of clinical experts recommends the long-term management strategy for advanced BCC patients treated with systemic therapy. The hedgehog inhibitors sonidegib and vismodegib are first-line treatments for advanced BCC with a long-lasting response, but long-term treatment with hedgehog inhibitors is often challenged by tolerability issues. However, several strategies for adverse effect management are available, such as dose interruptions, on-label alternate-day dosing and supportive medications. In conclusion, although BCC shows a high tumor mutational burden that favors a response to immunotherapy, experts recommend keeping patients on hedgehog inhibitors limiting immunotherapy to those who developed resistance during hedgehog inhibitor therapy or in case of persisting toxicity despite long-term management of adverse events.
2023
Inglese
Bossi, P., Ascierto, P. A., Basset-Seguin, N., Dreno, B., Dummer, R., Hauschild, A., Mohr, P., Kaufmann, R., Pellacani, G., Puig, S., Moreno-Ramirez, D., Robert, C., Stratigos, A., Gutzmer, R., Queirolo, P., Quaglino, P., Peris, K., Long-term strategies for management of advanced basal cell carcinoma with hedgehog inhibitors, <<CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY>>, 2023; 189 (september): 104066-N/A. [doi:10.1016/j.critrevonc.2023.104066] [https://hdl.handle.net/10807/249070]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/249070
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
social impact